203 related articles for article (PubMed ID: 22426498)
41. Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW).
Díez-Pérez A; Adachi JD; Adami S; Anderson FA; Boonen S; Chapurlat R; Compston JE; Cooper C; Gehlbach SH; Greenspan SL; Hooven FH; LaCroix AZ; Nieves JW; Netelenbos JC; Pfeilschifter J; Rossini M; Roux C; Saag KG; Silverman S; Siris ES; Wyman A; Rushton-Smith SK; Watts NB;
J Bone Miner Res; 2014 Jan; 29(1):260-7. PubMed ID: 23794198
[TBL] [Abstract][Full Text] [Related]
42. Dysmobility Syndrome Independently Increases Fracture Risk in the Osteoporotic Fractures in Men (MrOS) Prospective Cohort Study.
Buehring B; Hansen KE; Lewis BL; Cummings SR; Lane NE; Binkley N; Ensrud KE; Cawthon PM;
J Bone Miner Res; 2018 Sep; 33(9):1622-1629. PubMed ID: 29701911
[TBL] [Abstract][Full Text] [Related]
43. Association between incident and baseline vertebral fractures in European women: vertebral fracture assessment in the Osteoporosis and Ultrasound Study (OPUS).
Ferrar L; Roux C; Felsenberg D; Glüer CC; Eastell R
Osteoporos Int; 2012 Jan; 23(1):59-65. PubMed ID: 21732219
[TBL] [Abstract][Full Text] [Related]
44. Serum Levels of a Cathepsin-K Generated Periostin Fragment Predict Incident Low-Trauma Fractures in Postmenopausal Women Independently of BMD and FRAX.
Bonnet N; Biver E; Chevalley T; Rizzoli R; Garnero P; Ferrari SL
J Bone Miner Res; 2017 Nov; 32(11):2232-2238. PubMed ID: 28766739
[TBL] [Abstract][Full Text] [Related]
45. An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®.
Kaufman JM; Palacios S; Silverman S; Sutradhar S; Chines A
Osteoporos Int; 2013 Oct; 24(10):2561-9. PubMed ID: 23595562
[TBL] [Abstract][Full Text] [Related]
46. Does osteoporosis therapy invalidate FRAX for fracture prediction?
Leslie WD; Lix LM; Johansson H; Oden A; McCloskey E; Kanis JA;
J Bone Miner Res; 2012 Jun; 27(6):1243-51. PubMed ID: 22392538
[TBL] [Abstract][Full Text] [Related]
47. The effects of falls on the prediction of osteoporotic fractures: epidemiological cohort study.
Liu IT; Liang FW; Wang ST; Chang CM; Lu TH; Wu CH
Arch Osteoporos; 2021 Jul; 16(1):110. PubMed ID: 34245374
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of Radius Microstructure and Areal Bone Mineral Density Improves Fracture Prediction in Postmenopausal Women.
Biver E; Durosier-Izart C; Chevalley T; van Rietbergen B; Rizzoli R; Ferrari S
J Bone Miner Res; 2018 Feb; 33(2):328-337. PubMed ID: 28960489
[TBL] [Abstract][Full Text] [Related]
49. A discussion of the intervention thresholds in osteoporosis treatment in Poland.
Marcinkowska M; Ignaszak-Szczepaniak M; Wawrzyniak A; Dytfeld J; Marcinkowska WH; Ignaszak-Szczepaniak M; Wawrzyniak A; Dytfeld J; Horst-Sikorska W
Endokrynol Pol; 2011; 62(1):30-6. PubMed ID: 21365576
[TBL] [Abstract][Full Text] [Related]
50. Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW).
Siris ES; Gehlbach S; Adachi JD; Boonen S; Chapurlat RD; Compston JE; Cooper C; Delmas P; Díez-Pérez A; Hooven FH; Lacroix AZ; Netelenbos JC; Pfeilschifter J; Rossini M; Roux C; Saag KG; Sambrook P; Silverman S; Watts NB; Wyman A; Greenspan SL
Osteoporos Int; 2011 Jan; 22(1):27-35. PubMed ID: 20358360
[TBL] [Abstract][Full Text] [Related]
51. Assessment of the 10-year risk of fracture in Italian postmenopausal women using FRAX®: a north Italian multicenter study.
Pedrazzoni M; Girasole G; Giusti A; Barone A; Pioli G; Passeri G; Palummeri E; Bianchi G
J Endocrinol Invest; 2011 Dec; 34(11):e386-91. PubMed ID: 21750394
[TBL] [Abstract][Full Text] [Related]
52. The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study.
Cipriani C; Pepe J; Bertoldo F; Bianchi G; Cantatore FP; Corrado A; Di Stefano M; Frediani B; Gatti D; Giustina A; Porcelli T; Isaia G; Rossini M; Nieddu L; Minisola S; Girasole G; Pedrazzoni M
J Endocrinol Invest; 2018 Apr; 41(4):431-438. PubMed ID: 28956296
[TBL] [Abstract][Full Text] [Related]
53. Rationale of the Spanish FRAX model in decision-making for predicting osteoporotic fractures: an update of FRIDEX cohort of Spanish women.
Azagra R; Zwart M; Encabo G; Aguyé A; Martin-Sánchez JC; Puchol-Ruiz N; Gabriel-Escoda P; Ortiz-Alinque S; Gené E; Iglesias M; Moriña D; Diaz-Herrera MA; Utzet M; Manresa JM;
BMC Musculoskelet Disord; 2016 Jun; 17():262. PubMed ID: 27317560
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of teriparatide compared with risedronate on FRAX
Body JJ; Marin F; Kendler DL; Zerbini CAF; López-Romero P; Möricke R; Casado E; Fahrleitner-Pammer A; Stepan JJ; Lespessailles E; Minisola S; Geusens P
Osteoporos Int; 2020 Oct; 31(10):1935-1942. PubMed ID: 32474650
[TBL] [Abstract][Full Text] [Related]
55. Identification of patients with high osteoporosis risk: analysis of FRAX and phalangeal ultrasonography in a female population in North-East Italy.
Vogrig E; Della Martina M; Xodo S; Ganzitti LP; P Londero A; Fabiani G; Marchesoni D
Minerva Ginecol; 2014 Oct; 66(5):447-53. PubMed ID: 25245994
[TBL] [Abstract][Full Text] [Related]
56. Performance of FRAX in clinical practice according to sex and osteoporosis definitions: the Manitoba BMD registry.
Leslie WD; Majumdar SR; Morin SN; Lix LM; Schousboe JT; Ensrud KE; Johansson H; McCloskey EV; Kanis JA
Osteoporos Int; 2018 Mar; 29(3):759-767. PubMed ID: 29404625
[TBL] [Abstract][Full Text] [Related]
57. Measured height loss predicts incident clinical fractures independently from FRAX: a registry-based cohort study.
Leslie WD; Schousboe JT; Morin SN; Martineau P; Lix LM; Johansson H; McCloskey EV; Harvey NC; Kanis JA
Osteoporos Int; 2020 Jun; 31(6):1079-1087. PubMed ID: 32016485
[TBL] [Abstract][Full Text] [Related]
58. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
[TBL] [Abstract][Full Text] [Related]
59. [Ten-year fracture risk by FRAX(®) of women with osteoporosis attending osteoporosis care in Hungary].
Péntek M; Gulácsi L; Tóth E; Baji P; Brodszky V; Horváth C
Orv Hetil; 2016 Jan; 157(4):146-53. PubMed ID: 26772827
[TBL] [Abstract][Full Text] [Related]
60. FRAX underestimates fracture risk in patients with diabetes.
Giangregorio LM; Leslie WD; Lix LM; Johansson H; Oden A; McCloskey E; Kanis JA
J Bone Miner Res; 2012 Feb; 27(2):301-8. PubMed ID: 22052532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
